Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.36
CRIS's Cash-to-Debt is ranked lower than
77% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CRIS: 1.36 )
Ranked among companies with meaningful Cash-to-Debt only.
CRIS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.36  Med: 7.85 Max: No Debt
Current: 1.36
Equity-to-Asset 0.29
CRIS's Equity-to-Asset is ranked lower than
86% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRIS: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
CRIS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.7 Max: 0.95
Current: 0.29
0.12
0.95
Piotroski F-Score: 2
Altman Z-Score: -15.78
Beneish M-Score: -4.09
WACC vs ROIC
16.51%
-1164.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -810.45
CRIS's Operating Margin % is ranked lower than
75% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CRIS: -810.45 )
Ranked among companies with meaningful Operating Margin % only.
CRIS' s Operating Margin % Range Over the Past 10 Years
Min: -810.45  Med: -113.33 Max: -35.24
Current: -810.45
-810.45
-35.24
Net Margin % -841.04
CRIS's Net Margin % is ranked lower than
76% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. CRIS: -841.04 )
Ranked among companies with meaningful Net Margin % only.
CRIS' s Net Margin % Range Over the Past 10 Years
Min: -841.04  Med: -105.54 Max: -27.72
Current: -841.04
-841.04
-27.72
ROE % -174.87
CRIS's ROE % is ranked lower than
88% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CRIS: -174.87 )
Ranked among companies with meaningful ROE % only.
CRIS' s ROE % Range Over the Past 10 Years
Min: -174.87  Med: -29.93 Max: -11.29
Current: -174.87
-174.87
-11.29
ROA % -93.40
CRIS's ROA % is ranked lower than
84% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. CRIS: -93.40 )
Ranked among companies with meaningful ROA % only.
CRIS' s ROA % Range Over the Past 10 Years
Min: -93.4  Med: -25.84 Max: -10.23
Current: -93.4
-93.4
-10.23
ROC (Joel Greenblatt) % -15508.24
CRIS's ROC (Joel Greenblatt) % is ranked lower than
90% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. CRIS: -15508.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRIS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16681.33  Med: -2262.58 Max: -240.25
Current: -15508.24
-16681.33
-240.25
3-Year Revenue Growth Rate -32.10
CRIS's 3-Year Revenue Growth Rate is ranked lower than
79% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CRIS: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRIS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: -0.3 Max: 76.3
Current: -32.1
-39.7
76.3
3-Year EBITDA Growth Rate 63.30
CRIS's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. CRIS: 63.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRIS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.4  Med: -9.1 Max: 63.3
Current: 63.3
-49.4
63.3
3-Year EPS without NRI Growth Rate 44.20
CRIS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CRIS: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRIS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.5  Med: -11.9 Max: 44.2
Current: 44.2
-74.5
44.2
GuruFocus has detected 4 Warning Signs with Curis Inc $CRIS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRIS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:PETX, NAS:EDGE, NAS:OCUL, NAS:OVID, NAS:IDRA, NAS:CRBP, OTCPK:RCAR, OTCPK:VRSO, NAS:SVA, NAS:VYGR, NAS:CLDX, NAS:CNCE, OTCPK:NICXF, NAS:TIG, NAS:NVAX, NAS:SELB, NAS:CERS, OTCPK:TYMI, NAS:MRUS, NAS:ADXS » details
Traded in other countries:CUS.Germany,
Headquarter Location:USA
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.

Curis is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, breast cancers, and others.

Top Ranked Articles about Curis Inc

UPDATE - Curis to Present at the Jefferies Healthcare Conference
Curis to Present at the Jefferies Healthcare Conference
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting
Curis Reports First Quarter 2017 Financial Results
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 1 – 5, 2017 in Washington, D.C. Curis has exclusive license to CA-4948 under a collaboration agreement with Aurigene established in 2015.
Additional information follows. Abstracts can be accessed at www.aacr.org. Poster Presentation   Date/Time: Monday, Apr. 3, 2017, 8:00 AM - 12:00 PMSession Title: Novel Molecular Targets 1Session Category: Experimental and Molecular TherapeuticsPresentation Title: Efficacy of the IRAK4 Inhibitor CA-4948 in Patient-Derived Xenograft Models of
Diffuse Large B Cell LymphomaAbstract Number: 1168 About Curis, Inc. Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.

For More Information:

Company Contact:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
617-503-6500
[email protected]

Media Contact:
David Schull
Russo Partners
212-845-4271
[email protected]

Read more...
Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that James Dentzer, Chief Financial Officer and Chief Administrative Officer, will present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time in New York.
A corresponding webcast of the presentation can be accessed, both live and archived, by visiting: https://www.veracast.com/webcasts/opco/healthcare2017/03110203347.cfm The webcast will be archived shortly after the live event and will be available for 90 days through June 19, 2017. It will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com. About Curis, Inc. Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.  Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.  Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6597
[email protected]

Media Contact
David Schull
Russo Partners
(212) 845-4271
[email protected]

Read more...
Curis Reports Fourth Quarter and Year-End 2016 Financial Results

-- Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty -- -- Management to host conference call today at 8:30 a.m. EST -- LEXINGTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the fourth quarter and year ended December 31, 2016. "We are pleased with the progress we’ve made in advancing our pipeline in 2016. For CUDC-907 and CA-170, we remain focused on patient enrollment in their respective trials to assess their benefit in cancer patients.  The Phase 1 trial for CA-170 continues to progress on track through the dose escalation stage, and based on the early data, we have recently received regulatory approval to begin extension of the CA-170 Phase 1 study and enroll immunotherapy-naïve patients in Korea and Spain, with additional trial centers in other European countries projected to open in the second quarter.  The Phase 2 trial of CUDC-907 in patients with relapsed/refractory MYC-altered diffuse large B cell lymphoma, or DLBCL is nearing completion of patient enrollment, and our goal is to assess CUDC-907’s efficacy in this patient population, as measured by the overall response rate in up to 60 patients.   Depending on the Phase 2 trial results, we expect to hold discussions with the FDA regarding potential for accelerated approval of CUDC-907 as a monotherapy in this setting. In addition, we are completing IND-enabling studies of CA-327 and CA-4948,” said Ali Fattaey, Ph.D., Curis's CEO.” Dr. Fattaey continued, “Our collaboration with Aurigene continues to progress well. In September 2016, we completed a $24.5M financing with Aurigene. In October 2016, we licensed a second immuno-oncology program, and designated CA-327 as an oral small molecule development candidate targeting PDL1 and TIM3. We expect to file an IND for CA-327 in 2017.  Our IRAK4 kinase inhibitor development candidate, CA-4948, has progressed well in preclinical characterization and IND-enabling studies, and we expect to file an IND for CA-4948 in mid-2017." Royalty Financing Transaction On March 6, 2017, Curis entered into an agreement with HealthCare Royalty Partners (HCR), for a $45 million debt transaction secured with future Erivedge royalties. As part of this transaction, Curis’s wholly-owned subsidiary, Curis Royalty LLC, borrowed $45 million at an annual interest rate of 9.95% interest to be repaid solely with Erivedge royalty payments received from Genentech.  The transaction is expected to close later this month, at which time Curis would pay off the $18.4 million remaining balance on the existing loan from BioPharma-II. “Erivedge represents an effective and medically important product for patients suffering from advanced forms of basal cell carcinoma, and we are pleased to partner with Curis in providing this non-dilutive financing as the company funds its oncology pipeline,” said John Urquhart, Principal at HealthCare Royalty Partners. “We continue to focus our capital and resources in developing our pipeline of innovative cancer therapies.  We are especially pleased to work with HCR on this financing, which provides non-dilutive capital for our near-term development needs, while allowing us to retain the considerable upside potential in Erivedge.  In its fifth year on the market, Erivedge revenue grew 21% to CHF 203 million in 2016.  Genentech and Roche currently commercialize Erivedge in advanced basal cell carcinoma and are conducting clinical trials for its potential use in treating idiopathic pulmonary fibrosis and myelofibrosis,” said James Dentzer, Curis’s Chief Financial and Chief Administrative Officer.    Full Year and Fourth Quarter 2016 Financial Results For the year ended December 31, 2016, Curis reported a net loss of $60.4 million, or $(0.45) per share on both a basic and diluted basis, as compared to a net loss of $59.0 million, or $(0.48) per share on both a basic and diluted basis in 2015. For the fourth quarter of 2016, Curis reported a net loss of $11.3 million or $(0.08) per share on both basic and diluted basis, as compared to a net loss of $13.5 million, or $(0.10) per share on both basic and diluted basis for the same period in 2015. The net loss for the year ended December 31, 2016 includes a non-cash in-process research and development charge of $18.0 million related to the amendment of Curis's license agreement with Aurigene. The net loss for the year ended December 31, 2015, includes a non-cash in-process research and development charge of $24.3 million related to Curis's license agreement with Aurigene. Revenues for the year ended December 31, 2016 were $7.5 million, as compared to $7.9 million for the same period in 2015. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. Revenues for the fourth quarters of 2016 and 2015 were $2.4 million and $2.1 million, respectively. Operating expenses were $65.6 million for the year ended December 31, 2016, as compared to $64.4 million for the same period in 2015. Operating expenses for the fourth quarter of 2016 were $13.1 million, as compared to $15.3 million for the same period in 2015, and comprised the following: Costs of Royalty Revenues. Costs of royalty revenues, primarily amounts due to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales, were $0.4 million for both the years ended December 31, 2016 and 2015. Cost of royalty revenues for the fourth quarter of 2016 and 2015 were $0.1 million for both periods. Research and Development Expenses.  Research and development expenses were $31.6 million for the year ended December 31, 2016, as compared to $26.7 million for the same period in 2015. The increase was primarily due to increased direct spending related to clinical development activities of CUDC-907 and programs under the Aurigene collaboration over the prior year period. Employee-related expenses increased over the prior year period primarily due to additional headcount to support the multiple programs. Research and development expenses were $9.2 million for the fourth quarter of 2016 as compared to $12.0 million for the same period in 2015. In-Process Research and Development Expense. In-process research and development expense was $18.0 million for the year ended December 31, 2016, as compared to $24.3 million for the same period in 2015. These charges are associated with the stock issuances of 10,208,333 and 17,120,131 shares of Curis common stock to Aurigene, in 2016 and 2015 respectively. These shares were issued as consideration for the rights granted under the terms of the September 2016 amendment to the collaboration agreement and partial consideration for the rights granted under the terms of the January 2015 collaboration agreement, respectively. General and Administrative Expenses. General and administrative expenses were $15.6 million for the year ended December 31, 2016 as compared to $12.9 million for the same period in 2015. The increase in general and administrative expenses was driven primarily by higher personnel costs and stock-based compensation expense due to increased headcount, an increase in legal service costs and professional and consulting services. General and administrative expenses were $3.8 million for the fourth quarter of 2016, as compared to $3.2 million for the same period in prior 2015. Other expense, net was $2.4 million for the year ended December 31, 2016, as compared to $2.5 million for the same period in 2015. Other expense, net was $0.6 million and $0.2 million for the fourth quarter of 2016 and 2015, respectively.  Other expense, net primarily consisted of interest expense related to the loan made by BioPharma-II (an investment fund managed by Pharmakon Advisors) to Curis Royalty (a wholly owned subsidiary of Curis).    As of December 31, 2016, Curis's cash, cash equivalents and investments totaled $44.5 million and there were approximately 141.1 million shares of common stock outstanding. Recent Operational Highlights Curis - Aurigene collaboration: In January 2017, Curis exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January 2015.  The extension of exclusivity is associated with a payment of $7.5 million to Aurigene, payable in two equal installments. The first installment was paid in January 2017 and the second installment is estimated to be paid in the third quarter of 2017. CA-170 (PDL1/VISTA antagonist): In November 2016, Curis presented preliminary clinical pharmacokinetic (PK) and early biomarker data from the ongoing dose escalation stage of its Phase 1 trial of CA-170 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Clinical data from a limited number of patients demonstrated that, similar to the preclinical findings, orally-administered CA-170 has a dose proportional and predictable PK profile in patients treated at various escalating doses.  Additionally, analysis of patient blood samples showed that CA-170 is biologically active in modulating the immune system, with a several-fold increase in the percentage of circulating CD8 T cells expressing activation markers within 24 hours of oral dosing. CA-327 (PDL1/TIM3 antagonist): In November 2016, Curis collaborator, Aurigene presented pre-clinical data at the SITC Annual Meeting and EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium for CA-327, the development candidate targeting PDL1 and TIM3 immune checkpoints. The data from various in vitro and in vivo studies with CA-327 demonstrated potency and selectivity, oral bioavailability, desirable safety profile, and anti-tumor activity in multiple mouse syngeneic tumor models. CUDC-907 (HDAC/PI3K inhibitor): In December 2016, Curis presented non-clinical data from combination studies of CUDC-907 and venetoclax, a BH3 mimetic and BCL2 antagonist at the American Society of Hematology’s annual meeting.  In multiple DLBCL cell lines, the CUDC-907 and venetoclax combination exhibited synergistic activity resulting in reduced cell viability. The additive/ synergistic anti-tumor effects were also observed in vivo in mice bearing various DLBCL xenograft tumor models. Erivedge®: In November 2016, the European Commission granted full approval to Erivedge® (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. Erivedge was originally granted ‘conditional approval' in July, 2013 in the European Union. Erivedge was approved in the U.S. in 2012 for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation. Erivedge was developed and is marketed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Other: In November 2016, Curis announced the appointment of Lori A. Kunkel, M.D. to its Board of Directors. Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, Amphivera Therapeutics Inc., Tocagen Inc., and Harpoon Therapeutics.  In the past, Dr. Kunkel has served as CMO at Pharmacyclics, Inc., Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech. She has also spent a number of years in academic/clinical medicine. She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties. Upcoming Activities
Curis expects that it will make presentations at the following conferences through April 2017: Presentation of preclinical results from CA-4948 at the annual meeting of The American  Association of Cancer Research in April, 2017
Conference Call Information 
Curis management will host a conference call today, March 9, 2017, at 8:30 a.m. EST, to discuss these financial results, as well as provide a corporate update. To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 84640331. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. About HealthCare Royalty Partners
HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets. HCR has $3.4 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco and Boston. Over the past decade, HCR's senior professionals have completed more than 60 healthcare investments. For more information, visit www.healthcareroyalty.com.  About Curis, Inc. 
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors.  Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.  Curis is currently conducting a Phase 1 trial of CA-170in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.  Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the plans, strategies and objectives of management for future operations; the Company’s plans to advance its development programs, including the timing of IND filings for CA-327 and CA-4948; and the expected closing of the royalty financing transaction. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "seeks," "estimates," "assumes," "will," "may," "could" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, that Curis or Aurigene will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech's and/or Roche's ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. Curis faces risks relating to its wholly-owned subsidiary's royalty-collateralized loan transaction, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty-related payments as a result of a foreclosure of the loan. Curis requires substantial additional capital to fund its business in the near term and such capital may not be available on reasonable terms, or at all. Curis faces substantial competition. Curis also faces risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time consuming patent litigation and interference proceedings. Unstable market and economic conditions and unplanned expenses may adversely affect Curis's financial conditions. The royalty financing transaction with Healthcare Royalty may not close as anticipated.  Important factors that may cause or contribute to such differences include the factors set forth under the caption “Risk Factors” in our in our most recent Form 10-K and Form 10-Q and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission (“SEC”). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.                                                                                     CURIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except share and per share data)   Three months ended Year ended  December 31, December 31,  2016 2015 2016 2015Revenues:        Royalties $2,407  $2,033  $7,810  $8,031 Research and development, net (45) 59  (283) (153)Total revenues 2,362  2,092  7,527  7,878          Operating expenses:        Costs of royalty revenues 121  103  399  406 Research and development 9,159  12,041  31,590  26,699 In-process research and development -  -  17,989  24,348 General and administrative 3,845  3,194  15,588  12,906 Total operating expenses 13,125  15,338  65,566  64,359          Net loss from operations (10,763) (13,246) (58,039) (56,481)         Interest income 80  573  405  825 Interest expense (652) (788) (2,777) (3,325)Other expense, net (572) (215) (2,372) (2,500)Net loss (11,335) (13,461) (60,411) (58,981)         Basic and diluted net loss per common share $(0.08) $(0.10) $(0.45) $(0.48)Basic and diluted weighted average common shares outstanding 140,715,621  128,501,098  132,785,687  123,365,195 
CURIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands)   December 31, 2016 December 31, 2015ASSETS         Cash, cash equivalents and investments $44,485  $82,191 Investments – restricted 153  153 Accounts receivable 2,459  2,106 Property and equipment, net 413  278 Goodwill 8,982  8,982 Other assets 1,260  1,255 Total assets $57,752  $94,965      LIABILITIES AND STOCKHOLDERS’ EQUITY    Accounts payable, accrued expenses and other liabilities $8,626  $6,290 Debt obligations, net 19,860  24,165 Total liabilities 28,486  30,455 Total stockholders' equity 29,266  64,510      Total liabilities and stockholders' equity $57,752  $94,965   

For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc. 
617-503-6500
[email protected]

Media Contact
David Schull
Russo Partners
(212) 845-4271
[email protected]

Read more...
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2016 financial results on Thursday, March 9, 2017, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST, to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, CA-170, an oral small molecule antagonist of PD-L1/VISTA and other molecules under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2016.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 84640331. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in clinical studies in patients with lymphomas and solid tumors.  Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information:

James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
[email protected]

Media Contact:
David Schull
Russo Partners
212-845-4271
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 14.72
CRIS's PB Ratio is ranked lower than
89% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CRIS: 14.72 )
Ranked among companies with meaningful PB Ratio only.
CRIS' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 4.42 Max: 19.67
Current: 14.72
1.15
19.67
PS Ratio 38.28
CRIS's PS Ratio is ranked lower than
73% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. CRIS: 38.28 )
Ranked among companies with meaningful PS Ratio only.
CRIS' s PS Ratio Range Over the Past 10 Years
Min: 2.64  Med: 14.64 Max: 382
Current: 38.28
2.64
382
Current Ratio 5.86
CRIS's Current Ratio is ranked higher than
62% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CRIS: 5.86 )
Ranked among companies with meaningful Current Ratio only.
CRIS' s Current Ratio Range Over the Past 10 Years
Min: 2.89  Med: 7.35 Max: 25.89
Current: 5.86
2.89
25.89
Quick Ratio 5.86
CRIS's Quick Ratio is ranked higher than
64% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CRIS: 5.86 )
Ranked among companies with meaningful Quick Ratio only.
CRIS' s Quick Ratio Range Over the Past 10 Years
Min: 2.89  Med: 7.35 Max: 25.89
Current: 5.86
2.89
25.89
Days Sales Outstanding 101.01
CRIS's Days Sales Outstanding is ranked lower than
71% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. CRIS: 101.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRIS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.04  Med: 20.73 Max: 119.24
Current: 101.01
1.04
119.24
Days Payable 5.00
CRIS's Days Payable is ranked lower than
89% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. CRIS: 5.00 )
Ranked among companies with meaningful Days Payable only.
CRIS' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 3791.15 Max: 5381.69
Current: 5
5
5381.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.00
CRIS's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CRIS: -18.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRIS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -8.9 Max: -3.7
Current: -18
-43.8
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 37.00
CRIS's Price-to-Net-Cash is ranked lower than
90% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. CRIS: 37.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRIS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.78  Med: 6.84 Max: 46.33
Current: 37
1.78
46.33
Price-to-Net-Current-Asset-Value 24.67
CRIS's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CRIS: 24.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRIS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.78  Med: 6.41 Max: 30.89
Current: 24.67
1.78
30.89
Price-to-Tangible-Book 24.67
CRIS's Price-to-Tangible-Book is ranked lower than
92% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. CRIS: 24.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRIS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64  Med: 5.74 Max: 31.59
Current: 24.67
1.64
31.59
Price-to-Median-PS-Value 2.61
CRIS's Price-to-Median-PS-Value is ranked lower than
86% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CRIS: 2.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRIS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.14 Max: 21.07
Current: 2.61
0.09
21.07
Earnings Yield (Greenblatt) % -21.14
CRIS's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. CRIS: -21.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRIS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -188.7  Med: -11.85 Max: -0.1
Current: -21.14
-188.7
-0.1

More Statistics

Revenue (TTM) (Mil) $7.93
EPS (TTM) $ -0.48
Beta2.44
Short Percentage of Float3.52%
52-Week Range $1.47 - 3.72
Shares Outstanding (Mil)143.77

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 7 7
EPS ($) -0.46 -0.43
EPS without NRI ($) -0.46 -0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRIS

Headlines

Articles On GuruFocus.com
UPDATE - Curis to Present at the Jefferies Healthcare Conference Jun 01 2017 
Curis to Present at the Jefferies Healthcare Conference Jun 01 2017 
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting May 25 2017 
Curis Reports First Quarter 2017 Financial Results May 04 2017 
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017 Apr 28 2017 
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 05 2017 
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting Mar 30 2017 
Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference Mar 16 2017 
Curis Reports Fourth Quarter and Year-End 2016 Financial Results Mar 09 2017 
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on Marc Mar 07 2017 

More From Other Websites
ETFs with exposure to Curis, Inc. : June 26, 2017 Jun 26 2017
Top 3 Healthcare Penny Stocks for 2017 Jun 20 2017
UPDATE - Curis to Present at the Jefferies Healthcare Conference Jun 01 2017
Curis to Present at the Jefferies Healthcare Conference Jun 01 2017
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting May 25 2017
ETFs with exposure to Curis, Inc. : May 22, 2017 May 22 2017
Edited Transcript of CRIS earnings conference call or presentation 4-May-17 12:30pm GMT May 19 2017
Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Curis reports 1Q loss May 04 2017
Investor Network: Curis, Inc. to Host Earnings Call May 04 2017
Curis Reports First Quarter 2017 Financial Results May 04 2017
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017 Apr 28 2017
Curis, Inc. – Value Analysis (NASDAQ:CRIS) : April 25, 2017 Apr 25 2017
Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 24, 2017 Apr 24 2017
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 05 2017
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting Mar 30 2017
ETFs with exposure to Curis, Inc. : March 27, 2017 Mar 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}